By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharmaceuticals Announces Expansion Of VAL-083 Development Program To Include Ovarian Cancer 9/2/2015 6:57:37 AM
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015 6:36:29 AM
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015 8:08:38 AM
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015 6:30:26 AM
DelMar Pharmaceuticals Completes $2.6 Million Registered Direct Offering 8/20/2015 6:35:04 AM
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015 6:31:41 AM
DelMar Pharmaceuticals Announces Financing Update And Initial Subscriptions Of $2.0 Million In Registered Direct Offering 7/28/2015 10:36:45 AM
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015 9:10:39 AM
DelMar Pharmaceuticals To Present Updated Phase I/II Clinical Data On Val-083 In The Treatment Of Refractory Glioblastoma Multiforme At GBM2015: 2nd International Symposium On Clinical And Basic Investigation In Glioblastoma 7/9/2015 9:50:18 AM
BIO2015 EXCLUSIVE: DelMar Pharmaceuticals Files for $8M Fund Raise, BioSpace (DHX) Learns 6/17/2015 12:13:51 PM